Arena Pharma (ARNA) Announces Results of APD916 Phase 1; A Lower Dose May be Sufficient
Tweet Send to a Friend
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announces results from APD916 Phase 1.
Dose-limiting CNS adverse events occurred at the 5 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Dose-limiting CNS adverse events occurred at the 5 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
